Andrey Chursov, Ph.D.’s Post

How much benefit does TIGIT inhibition present when combined with traditional immunotherapy in esophageal cancer? The results of SKYSCRAPER-08, which looked at tiragolumab, a novel anti-TIGIT antibody, plus atezolizumab were recently presented.  Tiragolumab + atezolizumab + chemotherapy was compared to chemotherapy alone in unresectable recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).   The long-term results of KEYNOTE-590 were also recently presented, which compared pembrolizumab + chemotherapy to chemotherapy in locally advanced/metastatic esophageal cancer.  In the ESCC subgroup of KEYNOTE-590, the HR for OS was 0.71.  In SKYSCRAPER-08, the HR was 0.70.  Anti-TIGIT therapy probably has no role in esophageal squamous cell carcinoma, given that its trials in lung cancer were also negative. With the caveat, of course, that this is a cross-trial comparison... #keytruda #tecentriq #esophagealcancer https://lnkd.in/eds9Y6Wr https://lnkd.in/ebVk8XCh

Even with the Memorial Day holiday coming up, I'm already looking ahead to end of next week and the start of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It's always a busy and productive time, and this year's meeting includes a diverse set of presentations that I am excited to be a part of. In addition to being an invited panelist for the Caris Life Sciences Fellows Forum focused on career paths for early-career investigators and trainees, I will be a speaker at the Education Session taking place Saturday, June 1 from 1:15-2:30 pm, focused on Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates. The title of my talk will be: Dynamic Evaluation of Biomarkers in Patients Treated With Antibody-Drug Conjugates (ADCs). Looking forward to this session, as it focuses on an fast-growing form of developmental therapeutic class of cancer drugs. Join us in Hall D1 if you'll be at #ASCO24! with Chair and Speaker Dr. Giuseppe Curigliano, speaker Dr. Patricia LoRusso, Education Chair Dr. Thomas LeBlanc https://lnkd.in/gmADupWu #oncology #oncologist #cancer #cancertreatment #developmentaltherapeutics #tumorbiology #molecularlytargetedagents #cancerbiology #cancerbio #cancertherapy #cancertherapeutics #medicine #physicianscientist #mdphd #medicine #medical #ASCO #science #cancerscience #laboratory #lablife #medicalife

✨ Yesterday I was watching a super informative lecture from the American Society of Clinical Oncology (ASCO) Annual Meeting on #precisiononcology in #pediatric and #AYA #sarcomas by Dr. Jack Shern. Here are some key takeaways: 🔬 Dr. Shern highlighted the critical aspects of precision oncology, emphasizing its potential to provide accurate diagnoses, develop targeted therapies, and ultimately improve patient outcomes. This approach is particularly crucial for rare pediatric sarcomas, where personalized treatment strategies can make a significant difference. 🧬 Major international efforts involving comprehensive molecular profiling that aim to identify actionable alterations. #MAPPYACTS (Europe) #INFORM (Germany) #ZERO childhood cancer (Australia) National Cancer Institute (NCI) Pediatric #MATCH (USA) #KiCS (Canada) 📊 Key Findings: 🔹 37% of enrolled cases across these studies had a #sarcoma diagnosis. 🔹 33% of sarcoma cases had #actionable alterations, although the definition of "actionable" varied across studies. 🔹 #Germline alterations were identified in 10-20% of #pediatric and #AYA sarcoma cases. Challenges: 🔺 Limited Actionable Alterations. 🔺Implementation Barriers: High costs, accessibility, and inconsistent initiation of molecular testing. 🔺Underutilized Germline Testing: it often goes untested and uncounseled. etc 🔗 Key recommendations: 🔹Routine Molecular Profiling: Implementing comprehensive molecular profiling to ensure accurate diagnoses and prognostic assessments. 🔹Targeted Drug Strategies: Developing and refining targeted drug strategies and combination therapies specifically for sarcoma patients. 🔹Enhanced Patient and Family Engagement: Fostering transparent communication and shared decision-making processes with patients and their families. #ASCO2024 #pediatriconcology #precisionmedicine #childhoodcancer #sarcomaresearch #liquidbiopsy #genomicprofiling

💫 #ASCO2024 is just around the corner and here are some oral abstract sessions in #pediatriconcology to keep on your radar: 🔹 RMS13: A phase II trial using risk adapted focal proton beam radiation and/or surgery with the addition of maintenance chemotherapy in intermediate risk rhabdomyosarcoma Jessica Gartrell St. Jude Children's Research Hospital 🔹Outcome of children and young adults with localized extremity rhabdomyosarcoma treated on Children's Oncology Group trials  Rajkumar Venkatramani M.D. Children's Oncology Group 🔹 CINSARC score use in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in the Children’s Oncology Group (COG) studies ARST0332 and ARST1321 Rachel M Hurley Children's Hospital of Philadelphia 🔹 Brigatinib monotherapy in children with R/R ALK+ ALCL, IMT, or other solid tumors: Results from the BrigaPED (ITCC-098) phase 1 study Charlotte Rigaud ITCC Consortium 🔹 Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions Elizabeth Fox St. Jude Children's Research Hospital 🔹 Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors Karen D. Wright Dana-Farber Cancer Institute 🔹 Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial Olaf Witt Hopp Children’s Cancer Center Heidelberg (KiTZ) 🔹 Vincristine (VCR) pharmacokinetics (PK) in infants dosed using a body surface area (BSA) banded dosing table and in older children dosed based on BSA: A pediatric early phase clinical trial network study (PEPN22P1). Emily Blauel-Bocko Children's Hospital Colorado 🔹 Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial. Mark Ranalli Nationwide Children's Hospital 🔹 A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group Ami V. Desai The University of Chicago Medical Center Children's Oncology Group ✍ Add your list below! See you soon in #Chicago! American Society of Clinical Oncology (ASCO) International Society of Paediatric Oncology - SIOP OncoDaily POEM Group SIOP Europe, the European Society for Paediatric Oncology (SIOPE) #abstract #pediatriconcology #oralpresentation #sarcoma #neuroblastoma #CNStumors #precisionmedicine

While a direct comparison between the HARMONi-A and the ORIENT-31 study may not be appropriate, the PFS data from both studies are remarkably similar despite Akeso highlighting the unique mechanism of action of ivonescimab. ✅ HARMONi-A mPFS: 7.06 months vs 4.80 months (HR: 0.46, P < 0.0001) ✅ ORIENT-31 mPFS: 6.9 months vs 4.3 months (HR: 0.46, P < 0.0001) ORIENT-31: https://lnkd.in/gQxtMV6w

#ASCO24 #LungCancer I missed an important abstract. Was the market concerned about the side effects of the HARMONi-A study? The HARMONi-A study investigated EGFR+ NSCLC patients who progressed after third-generation EGFR-TKI treatment and included those who had not been exposed to systemic chemotherapy except for EGFR-TKIs. Although the 7-month mPFS showed some improvement compared to the five months typically seen in similar treatment lines, grade 3 or higher TEAEs were higher in the ivonescimab group (61.5% vs. 49.1%). During the four cycles of the induction period, patients received ivonescimab, pemetrexed, and carboplatin. As seen in the FLAURA2 study, this period is associated with many side effects. The frequency of these side effects significantly decreases after carboplatin is discontinued. However, considering the characteristics of second or third-line patients, the initial aggressive combination therapy might worsen their condition. The FLAURA2 study confirmed the efficacy of combining third-generation EGFR-TKIs with chemotherapy. This evidence allows us to consider combinations of EGFR-TKIs and ADCs, which several groups are already exploring. While we need to review the detailed data from HARMONi-A, these findings could provide BioNTech SE with intriguing insights. Abstract: 8508

How much do you really know about metastatic urothelial carcinoma (mUC)? Take The Ultimate mUC Challenge, curated by our esteemed faculty, Prof. Dr. Axel S. Merseburger and Professor Tom Powles, to find out! 🔎 Test your knowledge of the current management of mUC as you progress through a series of challenging multiple choice questions and collect antibody tokens with each correct guess. 🔎 Not sure which answer to choose? No problem! You have different lifelines at your disposal to help you throughout the game. 🔎 The goal is to accumulate the maximum number of antibodies possible. Do you have what it takes? Make the right choices and become a master of managing mUC. Try it now! at https://lnkd.in/edg3TJFC --- This programme is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany and Astellas. #mUC #urothelialcarcinoma #oncology #medicaleducation #continuingmedicaleducation #cne #independentmedicaleducation #ime #SpringerIME

Such a powerful SMC Talk!

Finish an interesting course

What is the difference between a good conference and an OK conference? Is it the venue? Is it the theme? Is it the speakers? As you prepare for your 2024 meetings, conferences, retreats, and professional development training consider all these things i.e. venue, theme, speakers, etc.. Word to the wise. Never underestimate the value of a dynamic speaker. Joyce E. Brooks is uniquely prepared to deliver a program that will be unforgettable and she is ready to travel. Now booking for 2024.